NCT01926626 (RIMA) is a Phase 2 clinical trial of Nicotine Patch in Nicotine Dependence, sponsored by Jed E. Rose.

Who is sponsoring NCT01926626?

NCT01926626 is sponsored by Jed E. Rose.

What drugs are being tested in NCT01926626?

Interventions in NCT01926626: Nicotine Patch, Moclobemide.

What condition does NCT01926626 study?

NCT01926626 studies Nicotine Dependence.

Is NCT01926626 still recruiting?

NCT01926626 is currently completed. Last updated 17 August 2017.

Are results published for NCT01926626?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2017-08-17 · How we verify

NCT01926626: RIMA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers

Completed Phase 2 Results posted Last updated 17 August 2017

What this trial tests

Phase 2 trial testing Nicotine Patch in Nicotine Dependence in 76 participants. Completed in 1 October 2014.

Timeline

1 September 2013

Primary endpoint
1 July 2014

1 October 2014

Quick facts

Lead sponsor	Jed E. Rose
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	76
Start date	1 September 2013
Primary completion	1 July 2014
Estimated completion	1 October 2014
Sites	3 locations across United States

Drugs / interventions tested

Nicotine Patch (nicotine-patch) — full drug profile →
Moclobemide (MOCLOBEMIDE) — full drug profile →

Conditions studied

Nicotine Dependence — all drugs for Nicotine Dependence →

Sponsor

Jed E. Rose

Who can join

Adults 18 to 65, female only, with Nicotine Dependence. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Continuous Four-week Abstinence From Smoking
Time frame: Weeks 6-10 post quit day
Number of participants who reported continuous four-week abstinence from smoking (weeks 6-10 post target quit date), confirmed by expired air carbon monoxide (CO).

Sponsor's own description

The proposed study will assess the efficacy of moclobemide, a selective, reversible MAO-A inhibitor, in facilitating smoking cessation in treatment-seeking female smokers. This rationale is based on several findings from previous work: 1) cigarette smoke contains constituents that inhibit both forms of the enzyme monoamine oxidase (MAO-A and MAO-B); 2) that severity of depression symptoms after smoking abstinence is correlated with the level of MAO-A inhibition previously obtained from smoking; 3) moclobemide, an MAO-A inhibitor was found efficacious in a smoking cessation treatment trial (Berlin et al., 1995); and 4) women show a greater association between smoking and depression than men and women smokers in our previous trials report smoking to alleviate symptoms of depression to a greater extent than men.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Nicotine Patch

Trials testing the same drug.

NCT06811038 — iCanQuit Smoking Cessation Among Hispanic Adults · Phase 3 · not yet recruiting
NCT06763536 — Oral Nicotine Pouches Versus Nicotine Replacement Therapy to Reduce Cigarette Use for Smokers in Rural Appalachia · NA · recruiting
NCT05587361 — Beta-Adrenergic Modulation of Drug Cue Reactivity · Phase 4 · recruiting
NCT04839198 — Using Machine Learning to Develop Just-in-Time Adaptive Interventions for Smoking Cessation · NA · completed
NCT05538910 — Defining Neurobiological Links Between Substance Use and Mental Illness · NA · recruiting

Other recruiting trials for Nicotine Dependence

Currently open trials in the same condition.

NCT07466875 — Auricular Stimulation for Nicotine Withdrawal in Psychiatric Inpatients · NA · recruiting
NCT07250230 — Effect of Perioperative High-dose Transdermal Nicotine Patch on Pain Sensitivity Among Male Abstinent Tobacco Smokers Un · NA · recruiting
NCT07040566 — A Trial of Varenicline for E-cigarette Cessation · Phase 2 · recruiting
NCT07001930 — Effects of Cannabidiol on Stress and Nicotine Withdrawal · Phase 1 · recruiting
NCT06765291 — Behavioral Intervention for Youth to Promote Vaping Cessation · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01926626 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jed E. Rose
Last refreshed: 17 August 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01926626.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing